Please enter your details to request more information

In Europe, the number of patients consuming medical cannabis is expected to increase by 230% per annum

Investment Available*

Limited Share Offer - 15p per share

UK Registered Company: 12111072

Investment Highlights

• We have a 4 Hectare secure growing facility located in Maseru under the watch eye of the Maluti Mountains of Lesotho in Southern Africa
• Perfect Growing Conditions - Ideal for altitude, climate, clean water, and skilled local labour
• High on Compliance - Valid medical cultivation licence meets import and export requirements
• Commercially Competitive - Prices that remain attractive at both farmgate and retail levels.
• Lean & Scalable Business Model - Our Phased expansion plan keeps fixed costs low and output responsive to market demand.

There’s a rapidly growing market in Europe for high-quality medical cannabis flower that meets strict EU-GMP and GACP standards. Demand for natural, pharmaceutical-grade products continues to rise, while consistent, compliant supply remains limited.

The global medical cannabis market is projected to reach £121,330,000,000 by 2033… That’s a CAGR of 21.30%**

Invest in one of the greatest medical revolutions of our time

Medical cannabis is driving a global transformation in prescriptive healthcare. Supported by progressive legislation, the industry is moving into the mainstream, opening high growth markets, disrupting established players, and creating a new and scalable healthcare frontier.

Source: Global News Wire

To be able to deal with your enquiry effectively we will need to contact you via telephone and/or email. By enquiring you consent to being contacted and you consent to your data being stored in accordance with European GDPR regulations. Privacy Policy

IMPORTANT: This document is intended solely for distribution in the United Kingdom and is directed only at: (i) investment professionals; as defined in Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion Order 2005) (“FPO”); (ii) high net worth companies, partnerships, unincorporated associations, and trustees of high value trusts under Article 49 of the FPO; and (iii) other persons lawfully entitled to receive it, including self-certified sophisticated investors and high net worth individuals (together, “Qualified Investors”). Persons who are not Qualified Investors must not act on or rely on this document. This promotion has not been approved by an authorised person. Reliance on it for the purpose of engaging in investment activity may expose individuals to a significant risk of losing all funds, limited to the capital invested, together with any dividends and growth in value. The information herein does not constitute, and should not be construed as, an offer to the public in the United Kingdom to buy or sell securities, nor a solicitation to engage in investment activity. Any investment opportunity will be made available only to Qualified Investors. Past performance does not guarantee future outcomes, as investment values can go down or up.